CD19 and acute lymphoblastic leukemia: CD19, a prevalent surface marker on B cell, is used to engineer the anti-CD19 CAR-T cell which was approved by US Food and Drug Administration (FDA) for treating diffuse large B cell lymphoma (DLBCL) and acute lymphocytic leukemia (ALL) diseases [14, 15].